2018-19 Section 7-Neoplastic and Inflammatory Diseases of the Head and Neck eBook

Original Investigation Research

Survival in Carcinoma of the Minor Salivary Gland

Table. Demographic and Clinicopathologic Characteristics by Histologic Subtype (continued)

Subtype, No. (%) of Patients

Adenocarcinoma a (n = 1313)

All (N = 5334)

ACC (n = 1228)

MEC (n = 1568)

Rare (n = 1225)

P Value b

Characteristic

Stage

Localized Regional

2121 (39.8) 2049 (38.4) 441 (8.3) 723 (13.6)

664 (50.6) 402 (30.6) 111 (8.5) 136 (10.4)

356 (29.0) 600 (48.9) 156 (12.7) 116 (9.4)

980 (62.5) 390 (24.9) 66 (4.2) 132 (8.4)

121 (9.9) 657 (53.6) 108 (8.8) 339 (27.7)

<.001

Distant Missing

Abbreviations: ACC, adenoid cystic carcinoma; MEC, mucoepidermoid carcinoma; SES, socioeconomic status. a Percentages have been rounded and may not total 100. b Calculated using the χ 2 test. c Indicates at least 7.6% of families living below the poverty line. d The remaining 1767 patients had missing grade or not otherwise specified. e Includes well and moderately differentiated tumors. f Includes poorly differentiated and undifferentiated tumors.

Figure 1. Ten-Year Unadjusted Cause-Specific Survival (CSS) Rate by Histologic Subtype

100

MEC Adenocarcinoma ACC

80

60

Other rare carcinomas

40

Survival Probability, %

20

0

0

25

50

75

100

125

Product-limit survival estimate addresses the 10-year unadjusted CSS rate for adenocarcinoma, mucoepidermoid carcinoma (MEC), adenoid cystic carcinoma (ACC), and other rare carcinomas. Cross-hatch marks indicate censoring.

Duration of Follow-up, mo

No. at risk

MEC Adenocarcinoma ACC Other rare carcinomas

1568 1313 1228 1225

1225

980 689 681 626

780 527 492 446

572 363 319 288

386 246 228 201

923 912 871

Figure 2. Five-Year Unadjusted Cause-Specific Survival (CSS) Rate by Surgical Treatment

100

Surgery, no RT

80

Surgery+RT

60

40

Survival Probability, %

20

0

Product-limit survival estimate addresses the 5-year unadjusted CCS rate for patients who underwent surgery vs surgery with radiotherapy (RT). Cross-hatch marks indicate censoring.

0

10

20

30

40

50

60

Duration of Follow-up, mo

No. at risk

Surgery, no RT Surgery+RT

2604 2628

2317 2331

1985 2108

1730 1923

1540 1727

1347 1580

1182 1431

improvedCSSwas found inpatientswithadenocarcinomawho underwent local tumor destruction (HR, 0.18; 95% CI, 0.08-

0.41), partial surgery (HR, 0.19; 95% CI, 0.10-0.35), and total surgery (HR, 0.33; 95% CI, 0.20-0.54).

(Reprinted) JAMA Otolaryngology–Head & Neck Surgery January 2016 Volume 142, Number 1

jamaotolaryngology.com

Copyright 2016 American Medical Association. All rights reserved.

15